Prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis.
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
21
10
2021
revised:
30
11
2021
accepted:
03
12
2021
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
•Benign metastasizing leiomyomatosis (BML) is a rare condition.•Treatment options have traditionally included surgical resection or hormonal based therapy.•Traditional chemotherapy for BML is ineffective.•Our patient has had a prolonged response of stable disease with the anti-VEGF therapy of bevacizumab.
Identifiants
pubmed: 35531358
doi: 10.1016/j.gore.2021.100903
pii: S2352-5789(21)00207-1
pmc: PMC9068955
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100903Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Br J Obstet Gynaecol. 1986 May;93(5):455-60
pubmed: 3085706
J Thorac Dis. 2016 Aug;8(8):E672-6
pubmed: 27621897
J Minim Invasive Gynecol. 2009 May-Jun;16(3):263-8
pubmed: 19423058
Respirol Case Rep. 2017 Jan 19;5(2):e00216
pubmed: 28116091
J Clin Endocrinol Metab. 2001 Nov;86(11):5405-11
pubmed: 11701714
Case Rep Obstet Gynecol. 2018 Oct 30;2018:5067276
pubmed: 30510824
Cureus. 2020 Apr 16;12(4):e7701
pubmed: 32431980
Pathol Res Pract. 1996 Mar;192(3):215-23
pubmed: 8739468
Am J Pathol. 1939 Jan;15(1):89-110.7
pubmed: 19970436
Acta Histochem. 2011 May;113(3):317-25
pubmed: 20106509
Cancer. 1980 Mar 1;45(5):932-7
pubmed: 7260844
Endocrinology. 2000 Oct;141(10):3852-61
pubmed: 11014242
BMC Res Notes. 2017 Dec 1;10(1):662
pubmed: 29191211
Steroids. 2003 Nov;68(10-13):817-24
pubmed: 14667973
Hum Reprod Update. 2014 Mar-Apr;20(2):194-216
pubmed: 24077979